Response to Szymczak et al. re: "A Case Report of Poor Response to Selpercatinib in the Presence of a 632_633 RET Deletion"

Ayanthi Wijewardene; Karine Bastard; Bin Wang; Matti Gild; Catherine Luxford; Anthony Gill; Bruce Robinson; Martyn Bullock; Roderick Clifton-Bligh

doi:10.1089/thy.2023.0325

Response to Szymczak et al. re: "A Case Report of Poor Response to Selpercatinib in the Presence of a 632_633 RET Deletion"

Thyroid. 2023 Dec;33(12):1496-1497. doi: 10.1089/thy.2023.0325. Epub 2023 Nov 16.

Authors

Ayanthi Wijewardene^{1

2

3}, Karine Bastard^{2

4}, Bin Wang^{5

6}, Matti Gild^{1

2

3}, Catherine Luxford², Anthony Gill^{3

7

8}, Bruce Robinson^{1

2

3}, Martyn Bullock^{2

3}, Roderick Clifton-Bligh^{1

2

3}

Affiliations

¹ Department of Endocrinology, Royal North Shore Hospital, Sydney, Australia.
² Cancer Genetics Laboratory, Kolling Institute, University of Sydney, Sydney, Australia.
³ Faculty of Medicine, University of Sydney, Sydney, Australia.
⁴ University of Sydney School of Pharmacy, Sydney, Australia.
⁵ Precision Medicine, Syd Path, St Vincent's Hospital, Sydney, Australia.
⁶ St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
⁷ Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, Australia.
⁸ NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, Sydney, Australia.

PMID: 37597210
DOI: 10.1089/thy.2023.0325

No abstract available